Transforming Drug Discovery
with AI-Enabled Multiomics
An AI-enabled precision medicine biotech company
for complex diseases
Dysregulation in the microbiome-gut interface is involved in disease causation and therapeutic outcomes in multiple disease areas.
Piton’s proprietary drug candidates act on specific targets in disease-causing pathways in the gut.
Our disease areas
Inflammatory
Ulcerative Colitis
5M
Global Cases
>2M
Eligible Patients
>20%
Bowel Resection Rate
<50%
Efficacy of Current Drugs
There is no cure or effective treatment for Ulcerative Colitis. Existing therapeutic strategies target the symptoms of this disease, restricting or suppressing the patient’s immune response.
Piton is the first therapeutic strategy that targets the gut lumen with gut-restricted small molecules, with minimal adverse side effects.
Neurological
Autism
Parkinson’s
>80M
Eligible Patients
10M
Global Cases
2.8%
US Children
1%
Humanity
There is no cure or effective treatment for ASD. ASD is associated with socialization deficits, anxiety and restricted or repetitive behaviors or interests.
Piton’s candidate molecules demonstrate significant restoration of socialization measures with improvements in anxiety in ASD animal models.
Metabolic
Diabetes
Obesity
10M
Global Cases
~400M
Eligible Patients
<50%
Multi-morbidities
>1B
Obesity Prevalence
Piton’s current focus is on the treatment of Type-2 Diabetes. Approximately 520 million people have type-2 diabetes. There is no cure for this disease.
Independently conducted research suggests that Piton’s therapeutic strategy for UC may also be applicable in the treatment of Type-2 Diabetes. This medication would be a highly differentiated, first-in-class drug targeting a MOA in the gut microbiome.
The company is actively exploring the therapeutic potential of our lead compound for the treatment of Type-2 Diabetes.
Fathom Platform
Piton’s unique capabilities are realizing the untapped potential of microbiome-focused therapeutics. The company is a leader in the development of a new category of therapeutic modalities of orally delivered, small and large molecules that precisely target specific disease-causing mechanisms.
Discovery and drug development activities are efficiently and effectively facilitated by Piton’s proprietary Fathom Platform.
Fathom Platform technology
The Company’s novel and highly differentiated Fathom platform operates a technical stack in which analyzes multi-modal data and metadata acquired from clinical studies.
Precision drugs that target causal mechanisms in the gut microbiome.
Piton Therapeutics decodes microbiome signals to develop precision small molecule drugs for serious diseases with defined mechanisms of action. By translating microbiome insights into rationally designed therapeutics, we aim to transform patient care with novel, mechanism-driven treatments